Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, Mosna F, Leoncin M, Stulle M, Griguolo D, Pravato S, Trentin L, Lazzarotto D, Di Bona E, Sancetta R, Lucchini E, Poiani M, Palmieri C, Zaja F. De Bellis E, et al. Among authors: pravato s. Leuk Res. 2022 Apr;115:106811. doi: 10.1016/j.leukres.2022.106811. Epub 2022 Feb 24. Leuk Res. 2022. PMID: 35219543 No abstract available.
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.
Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: pravato s. Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18. Br J Cancer. 2019. PMID: 31209327 Free PMC article.
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, Frezzato F, Trimarco V, Severin F, Raggi F, Scomazzon E, Pravato S, Piazza F, Semenzato G, Trentin L. Visentin A, et al. Among authors: pravato s. Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):678-685.e4. doi: 10.1016/j.clml.2019.03.002. Epub 2019 Mar 11. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31371221
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A, Frezzato F, Severin F, Imbergamo S, Pravato S, Romano Gargarella L, Manni S, Pizzo S, Ruggieri E, Facco M, Brunati AM, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: pravato s. Onco Targets Ther. 2020 Sep 29;13:9679-9688. doi: 10.2147/OTT.S268899. eCollection 2020. Onco Targets Ther. 2020. PMID: 33061448 Free PMC article. Review.
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: pravato s. Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21. Am J Hematol. 2022. PMID: 34904743 Free article. Clinical Trial. No abstract available.
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, Mosna F, Leoncin M, Stulle M, Griguolo D, Pravato S, Trentin L, Lazzarotto D, Di Bona E, Bassan R, Lucchini E, Poiani M, Palmieri C, Zaja F. De Bellis E, et al. Among authors: pravato s. Leuk Res. 2022 Mar;114:106803. doi: 10.1016/j.leukres.2022.106803. Epub 2022 Feb 8. Leuk Res. 2022. PMID: 35150967 Free article.
Anaemia during venetoclax ramp-up phase: Do not forget unusual causes.
Cavarretta CA, Visentin A, Pravato S, Piva E, Piazza F, Basso D, Trentin L. Cavarretta CA, et al. Among authors: pravato s. Int J Lab Hematol. 2022 Oct;44(5):e211-e214. doi: 10.1111/ijlh.13875. Epub 2022 May 11. Int J Lab Hematol. 2022. PMID: 35538897 No abstract available.
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol.
Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, Fracchiolla NS, Forghieri F, Candoni A, Mengarelli A, Martelli MP, Venditti A, Carella AM, Albano F, Mancini V, Massimo B, Arena V, Sargentini V, Sciumè M, Pastore D, Todisco E, Roti G, Siragusa S, Ladetto M, Pravato S, De Bellis E, Simonetti G, Marconi G, Cerchione C, Fazi P, Vignetti M, Amadori S, Martinelli G, Voso MT. Messina M, et al. Among authors: pravato s. Cancers (Basel). 2022 Jun 18;14(12):3012. doi: 10.3390/cancers14123012. Cancers (Basel). 2022. PMID: 35740677 Free PMC article.
27 results